Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study

Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study

Purpose: In the MONALEESA-3 Phase III trial of patients with hormone receptor–positive human epidermal growth factor receptor–negative advanced breast cancer, ribociclib plus fulvestrant significantly improved progression-free survival (PFS) and overall survival (OS). Here, we present patient-report...

Full description

Bibliographic Details
Main Authors: Peter A. Fasching, J. Thaddeus Beck, Arlene Chan, Michele De Laurentiis, Francisco J. Esteva, Guy Jerusalem, Patrick Neven, Xavier Pivot, Giulia V. Bianchi, Miguel Martin, David Chandiwana, Brad Lanoue, Antonia Ridolfi, Yingbo Wang, Karen Rodriguez Lorenc, Arnd Nusch
Format: Article
Language:English
Published: Elsevier 2020-12-01
Series:Breast
Subjects:
Breast cancer
Metastatic
Patient-reported outcomes
Quality of life
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977620301867

Internet

http://www.sciencedirect.com/science/article/pii/S0960977620301867

Similar Items